Accumulation of boron in human malignant glioma cells in vitro is cell type dependent

Journal of Neuro-Oncology

Volumn 68, Issue 3, 2004, Pages 199-205

  Dahlström, Maria ^a   Capala, Jacek ^b,c   Lindström, Peter ^d   Wasteson, Åke ^a   Lindström, Annelie ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Studsvik Medical AB ^*  (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d LINKÖPING INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

BNCT; BPA; Fibroblasts; Glioblastoma multiforme; Glioma cell lines; In vitro

Indexed keywords

BORON 10; BORON DERIVATIVE; PHENYLALANINE;

ARTICLE; ATOMIC EMISSION SPECTROMETRY; CANCER CELL CULTURE; CELL HETEROGENEITY; CELL SEPARATION; CELL SUBPOPULATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DETERMINATION; DRUG UPTAKE; FIBROBLAST; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; NEUTRON CAPTURE THERAPY; RADIATION ENERGY; TARGET CELL; TUMOR VASCULARIZATION;

BORANES; BORON; BORON NEUTRON CAPTURE THERAPY; BRAIN NEOPLASMS; CELL LINE; CELL LINE, TUMOR; FIBROBLASTS; GLIOBLASTOMA; GLIOMA; HUMANS; PHENYLALANINE;

EID: 3042736593     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NEON.0000033489.54011.6b     Document Type: Article

References (20)

1. Pontén J, Westermark B: Properties of human malignant glioma cells in vitro. (Review article). Med Biol 56: 184-193, 1978
2. Nistér M, Wedell B, Betsholtz C, Bywater M, Pettersson M, Westermark B, Mark J: Evidence for progressional changes in the human malignant glioma line U-343MGa: analysis of karyotype and expression of genes encoding the subunit chains of platelet-derived growth factor. Cancer Res 47: 4953-4960, 1987
3. Shapiro JR, Mehta BM, Ebrahim SAD, Scheck AC, Moots PL, Fiola MR: Tumor heterogeneity and intrinsically chemoresistant subpopulations in freshly resected human malignant gliomas. In: Sudilovsky O et al. (eds) Boundaries between Promotion and Progression during Carcinogenesis. Plenum Press, New York, 1991
4. Coderre JA, Morris GM: The radiation biology of boron neutron capture therapy. Radiat Res 151: 1-18, 1999
5. Gahbauer R, Gupta N, Blue T, Goodman J, Barth R, Grecula J, Soloway AH, Sauerwein W, Wambersie A: Boron neutron capture therapy: principles and potential. Recent Results Cancer Res 150: 183-209, 1998
6. Barth RF, Soloway AH, Goodman JH, Gahbauer RA, Gupta N, Blue TE, Yang W, Tjarks W: Boron neutron capture therapy of brain tumours - an emerging therapeutic modality. Neurosurgery 44: 433-451, 1999
7. 10B-paraboronophenylalanine with special reference to evaluation of radiation dose and damage to normal skin. Radiat Res 138: 435-442, 1994
8. 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients: a study of boron neutron capture therapy for malignant melanoma. Melanoma Res 9: 75-83, 1999
9. Chanana AD, Capala J, Chadha M, Coderre JA, Diaz AZ, Elowitz EH, Iwai J, Joel DD, Liu HB, Ma R, Pendzick N, Peress NS, Shady MS, Slatkin DN, Tyson GW, Wielopolski L: Boron neutron capture therapy for glioblastoma multiforme: interim results from the phase I/II dose-escalation studies. Neurosurgery 44: 1182-1193, 1999
10. Busse PM, Harling OK, Palmer MR, Kiger WS, Kaplan J, Kaplan I, Chuang CF, Goorley JT, Riley KJ, Newton TH, Santa Cruz GA, Lu X-Q and Zamenhof RG: A critical examination of the results from Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease. J Neurooncol 62: 111-121, 2003
11. Capala J, Stenstam H.-B, Sköld K, Munck af Rosenschöld P, Giusti V, Persson C, Wallin E, Brun A, Franzen L, Carlsson J, Salford L, Ceberg C, Persson B, Pellettieri L, Henriksson R: Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden. J Neurooncol 62: 135-144, 2003
12. Joensuu H, Kankaanranta L, Seppala T, Auterinen I, Kallio M, Kulvik M, Laakso J, Vahatalo J, Kortesniemi M, Kotiluoto P, Seren T, Karila J, Brander A, Jarviluoma E, Ryynanen P, Paetau A, Ruokonen I, Minn H, Tenhunen M, Jaaskelainen J, Farkkila M, Savolainen S: Boron Neutron Capture Therapy of brain tumours: clinical trials at the Finnish facility using boronophenylalanine. J Neurooncol 62: 123-134, 2003
13. Snyder HR, Reedy AJ, Lennarz WMJ: Synthesis of aromatic boronic acids. Aldehydo boronic acids and a boronic acid analog of tyrosine. J Am Chem Soc 80: 835-838, 1958
14. Coderre JA, Glass JD, Fairchild RG, Micca PL, Fand I, Joel DD: Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumours other than melanoma. Cancer Res 50: 138-141, 1990
15. Papaspyrou M, Feinendegen LE, Müller-Gärtner H-W: Preloading with L-tyrosine increases the uptake of boronophenylalanine in mouse melanoma cells. Cancer Res 54: 6311-6314, 1994
16. Sjöberg S, Carlsson J, Ghaneolhosseini H, Gedda L, Hartman T, Malmquist J, Naeslund C, Olsson P, Tjarks W: Chemistry and biology of some low molecular weight boron compounds for boron neutron capture therapy. J Neurooncol 33: 41-52, 1997
17. Mehta SC, Lu RD: Targeted drug delivery for boron neutron capture therapy. Pharm Res 13: 344-351, 1996
18. Capala J, Makar MS, Coderre JA: Accumulation of boron in malignant and normal cells incubated in vitro with boronophenylalanine, mercaptoborane or boric acid. Radiat Res 146: 554-560, 1996
19. Wittig A, Sauerwein WA, Coderre JA: Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. Radiat Res 153: 173-180, 2000
20. Soloway AH, Tjarks W, Barnum BA, Rong F-G, Barth RF, Codogni IM, Wilson JG: The chemistry of neutron capture therapy. Chem Rev 98: 1515-1562, 1998